Investors May Recover Losses in Disc Medicine Stock
Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine Inc. (NASDAQ: IRON) shareholders due to allegations of materially misleading business information.
New York, NY – September 12, 2026 – Investors who have suffered losses in Disc Medicine, Inc. (NASDAQ: IRON) are encouraged to contact The Rosen Law Firm. The firm is investigating allegations that Disc Medicine may have issued materially misleading business information to the public.
Shareholders who purchased Disc Medicine securities may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action lawsuit seeking to recover investor losses.
The investigation stems from a February 13, 2026, Complete Response Letter (CRL) issued by the U.S. Food and Drug Administration (FDA) to Disc Medicine. The FDA stated it could not approve the company's new drug application for its bitopertin program, citing uncertainties requiring additional evidence.
Following this news, Disc Medicine's stock price fell 22% on February 13, 2026. Investors seeking to join the potential class action or learn more about their rights are urged to contact The Rosen Law Firm.